Appili Therapeutics Inc. (OTCMKTS:APLIF) Short Interest Up 584.7% in March

Appili Therapeutics Inc. (OTCMKTS:APLIF) saw a significant increase in short interest in March. As of March 15th, there was short interest totalling 121,200 shares, an increase of 584.7% from the February 28th total of 17,700 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily volume of 83,500 shares, the days-to-cover ratio is currently 1.5 days.

Appili Therapeutics Price Performance

Shares of OTCMKTS APLIF opened at $0.03 on Thursday. Appili Therapeutics has a 1-year low of $0.01 and a 1-year high of $0.05. The business’s 50 day moving average is $0.02 and its two-hundred day moving average is $0.02. The stock has a market capitalization of $3.41 million, a P/E ratio of -1.41 and a beta of -0.55.

About Appili Therapeutics

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.